CXCR4 拮抗剂市场：现况分析与预测（2024-2032）

预计预测期内（2024-2032 年），CXCR4 拮抗剂市场将以 12.37% 的显着复合年增长率成长。这主要是为了增加对新进展和技术的瞭解，从而增强製药公司正在进行的研究和开发以及 CXCR4 拮抗剂对癌症、爱滋病毒和其他慢性发炎疾病的治疗开发。和市场占有率。此外，监管机构的支持不断增加，进一步推动了 CXCR4 拮抗剂市场的显着成长。

依类型，市场分为 Plerixafor 和其他。普乐沙福（Plerixafor），又称莫佐韦（Mozovir），由于在动员造血干细胞进行移植方面有着良好的记录，因此拥有很大的市场占有率。建议与粒细胞集落刺激因子（G-CSF）一起使用或单独使用，并于2008年获得FDA批准。是多发性骨髓瘤患者的首选药物。不过，由 BL-8040（Motixafortide）、Mavorixafor 和其他产品组成的 "其他" 部分预计未来将会成长。这是因为最近进行了涉及这些药物的临床试验及其在其他治疗领域的潜在应用。较新的药物可能具有更好的疗效和安全性，从而提供新的治疗选择，推动未来的市场成长。

市场依应用分为癌症、爱滋病毒、慢性发炎疾病和其他疾病。其中，肿瘤领域占据CXCR4拮抗剂市场的最大占有率。这项优势的出现正值乳癌和肺癌等各类癌症的发生率不断上升之际，CXCR4拮抗剂正被用于预防肿瘤转移和解决与化疗抗药性相关的问题。然而，预计爱滋病毒领域将成为预测期内成长最快的领域。这一增长是由 HIV 感染发病率的不断上升以及对结合 CXCR4 拮抗剂以优化 HIV 治疗效果的 HIV 疗法的持续需求所推动的。

根据分销管道，市场分为医院药房、零售药房和线上药房。在这些细分市场中，医院药房占据最大的市场占有率，因为这些机构为医疗机构提供有价值的服务。我们供应和分发用于治疗癌症患者的重要药物，例如莫佐韦（CXCR4拮抗剂）。然而，由于消费者对便利性和移动性的偏好，线上药局市场的价值预计未来几年将大幅成长。新冠肺炎疫情加速了数位医疗服务的使用，并促使更多患者在线上购买药品。

为了更瞭解CXCR4 拮抗剂（如普乐沙福）的市场渗透率，市场被细分为北美（美国、加拿大和北美其他地区）、欧洲（德国、法国、英国、西班牙、义大利和北美其他地区）。由于癌症发生率不断增加，尤其是在中国和印度等国家，预计预测期（2024-2032 年）亚太地区将以显着的复合年增长率增长。 CXCR4 拮抗剂市场专注于协作开发活动，以改善产品开发并带来新药。例如，2021年11月，和誉生物科技股份有限公司与X4 Pharmaceuticals, Inc.合作开发CXCR4拮抗剂。

参与市场的主要公司包括 Sanofi、Teva Pharmaceutical Industries Ltd.、X4 Pharmaceuticals, Inc.、BioLineRx Ltd.、Merck KGaA、GPCR Therapeutics、AdAlta Limited、Spexis Ltd.、GlycoMimetics、Abbisko Therapeutics Co. .Ltd、 ETC .Ltd、 ETC .Ltd. 。

目录

第一章 市场介绍

• 市场定义
• 主要目的 利害关係人
• 限制

第 2 章 研究方法或假设

• 研究过程
• 研究方法
• 受访者资料

第 3 章执行摘要

• 产业摘要
• 各细分市场的展望
  • 市场成长强劲
• 区域展望

第 4 章 市场动态

• 驱动程式
• 机会
• 阻碍因素
• 趋势
• PESTEL 分析
• 需求方分析
• 供给面分析
  • 合作协议和协作活动
  • 投资场景

第 5 章 全球 CXCR4 拮抗剂市场收入（2022-2032）

第 6 章 市场洞察：按类型

• Plerixafor
• 其他

第 7 章市场洞察：按应用

• 癌症
• 爱滋病毒
• 慢性发炎性疾病
• 其他

第 8 章。

• 医院药房
• 零售药局
• 在线

第 9 章。

• 北美洲
  • 美国
  • 加拿大
  • 其他北美地区
• 欧洲
  • 德国
  • 英国
  • 法国
  • 义大利
  • 西班牙
  • 其他欧洲地区
  亚太地区
  • 中国
  • 日本
  • 印度
  • 其他亚太地区
• 世界其他地区

第 10 章 价值链分析

第 11 章 竞争格局

• 竞争资讯中心
• 竞争市场定位分析
• 波特五力分析

第 12 章 公司简介

• Sanofi
  • 公司概况
  • 关键财务讯息
  • SWOT 分析
  • 产品组合
  • 最新趋势
• Teva Pharmaceutical Industries Ltd.
• X4 Pharmaceuticals, Inc.
• BioLineRx Ltd.
• Merck KGaA
• GPCR Therapeutics
• AdAlta Limited
• Spexis Ltd.
• GlycoMimetics
• Abbisko Therapeutics Co. Ltd.

第 13 章 缩写与先决条件

第 14 章附录

CXCR4 antagonists are substances that bind to the CXCR4 receptor, a G-protein subfamily that is involved in a number of cellular functions for instance, inflammation and metastasis. As CXCR4 antagonists occlude this receptor, they lock out the interaction with its ligand CXCL12 which plays a role in cell migration and metastasis. This mechanism is especially noteworthy in oncology since the focalization through CXCR4 promotes the migration of cancer cells to appropriate niches. To date, the most well-known CXCR4 inhibitor is Plerixafor (AMD3100), which was approved by the FDA in 2008 to stimulate the mobilization of hematopoietic stem cells in patients preparing to undergo autologous transplant. Other candidates in the same class such as BL-8040 have been also tested in clinical trials for different types of cancer including leukemia and pancreatic cancer. These antagonists not only imbalanced tumor-stroma relationships but also promoted tumor immune therapy by attracting immune cells inside the tumor tissue. Newer emphasis has been directed towards novel non-peptide CXCR4 antagonists and their role in the management of cancers through targeting of anti-apoptotic CXCL12/CXCR4 signaling axis and reduction in metastasis and better therapeutic response against chemo-resistant tumors.

The CXCR4 Antagonist Market is expected to grow with a significant CAGR of 12.37% during the forecast period (2024-2032). This is mainly due to the continuous research and development by pharmaceutical companies, along with increased mergers and acquisitions activities to boost their capacities and shares to increase their knowledge of new advancements and technologies, which can enhance the development of CXCR4 antagonists' therapeutics for cancer, HIV and other chronic inflammatory diseases. Moreover, the growing support from the regulatory bodies is further assisting in the significant growth of the CXCR4 antagonist market.

Depending on the Type the market is divided into two types namely the Plerixafor and Others. Plerixafor, which is also known as Mozobil, occupies a large market share because of its proven performance in the mobilization of hematopoietic stem cells for transplantation. Recommended for use with or without the support of granulocyte colony stimulating factor (G-CSF) it received FDA approval in 2008, and it is the first choice for patients with lymphoma or multiple myeloma who do not receive adequate mobilization by G-CSF alone. However, the "Others" segment, comprising BL-8040 (Motixafortide), Mavorixafor, and other products is predicted to grow in the future, and this is attributed to recent clinical trials involving the drugs and their potential application in other therapeutical areas. Newer agents may be associated with better efficacy or safety and hence provide additional therapeutic choices, to fuel market growth in the future.

Based on the Application, the market is segmented into cancer, HIV, chronic inflammatory disease, and others. Out of these cancer segments hold the maximum share in the CXCR4 antagonist market. This dominance is due to the rising prevalence of different types of cancer including breast and lung cancer, which has the use of CXCR4 antagonists that prevent metastasis of tumors and tackle issues related to chemotherapy resistance. However, the HIV segment is expected to be the fastest-growing segment in the forecasted period. This growth is attributed to the increasing incidence of HIV infections and the continued demand for HIV treatments that incorporate CXCR4 antagonists to optimize the outcomes of HIV treatment.

According to the distribution channel, the market is categorized into hospital pharmacies, retail pharmacies, and online segments. Out of these segments, the hospital pharmacy has taken the largest market share because these institutions offer invaluable services to healthcare organizations. They offer and dispense the needed medicine such as Mozobil (CXCR4 antagonist), which is important in treating patients with cancer. However, it is predicted that the value of the online pharmacy segment will rise significantly in the future due to customer orientation toward convenience and mobility. The outbreak of COVID-19 advanced the utilization of digital health services, pushing additional patients to purchase medications online.

For a better understanding of the market penetration of CXCR4 antagonists such as Plerixafor, the market is analyzed based on its worldwide presence in countries such as North America (U.S., Canada, and the Rest of North America), Europe (Germany, France, U.K., Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. Asia-Pacific is expected to grow with a significant CAGR in the forecast period (2024-2032) owing to the growing incidence of cancer, especially in countries like China and India. The emphasis is made on the development of collaboration activities to improve the product development in the CXCR4 antagonist market for bringing new drug. For instance, in November 2021, Abbisko Therapeutics Co. Ltd., which is a China-based biopharmaceutical company, Joined hands with X4 Pharmaceuticals, Inc. for the development of CXCR4 antagonists.

Some of the major players operating in the market include Sanofi, Teva Pharmaceutical Industries Ltd., X4 Pharmaceuticals, Inc., BioLineRx Ltd., Merck KGaA, GPCR Therapeutics, AdAlta Limited, Spexis Ltd., GlycoMimetics, Abbisko Therapeutics Co. Ltd.

TABLE OF CONTENTS

1.MARKET INTRODUCTION

• 1.1. Market Definitions
• 1.2. Main Objective
• 1.3. Stakeholders
• 1.4. Limitation

2.RESEARCH METHODOLOGY OR ASSUMPTION

• 2.1. Research Process of the CXCR4 Antagonist Market
• 2.2. Research Methodology of the CXCR4 Antagonist Market
• 2.3. Respondent Profile

3.EXECUTIVE SUMMARY

• 3.1. Industry Synopsis
• 3.2. Segmental Outlook
  • 3.2.1. Market Growth Intensity
• 3.3. Regional Outlook

4.MARKET DYNAMICS

• 4.1. Drivers
• 4.2. Opportunity
• 4.3. Restraints
• 4.4. Trends
• 4.5. PESTEL Analysis
• 4.6. Demand Side Analysis
• 4.7. Supply Side Analysis
  • 4.7.1. Partnership agreements and collaboration activities
  • 4.7.2. Investment Scenario

5.GLOBAL CXCR4 ANTAGONIST MARKET REVENUE (USD MN), 2022-2032F

6.MARKET INSIGHTS BY TYPE

• 6.1. Plerixafor
• 6.2. Others

7.MARKET INSIGHTS BY APPLICATION

• 7.1. Cancer
• 7.2. HIV
• 7.3. Chronic Inflammatory Disease
• 7.4. Others

8.MARKET INSIGHTS BY DISTRIBUTION CHANNEL

• 8.1. Hospital Pharmacies
• 8.2. Retail Pharmacies
• 8.3. Online

9.MARKET INSIGHTS BY REGION

• 9.1. North America
  • 9.1.1. U.S.
  • 9.1.2. Canada
  • 9.1.3. Rest of North America
• 9.2. Europe
  • 9.2.1. Germany
  • 9.2.2. U.K.
  • 9.2.3. France
  • 9.2.4. Italy
  • 9.2.5. Spain
  • 9.2.6. Rest of Europe
• 9.3. Asia-Pacific
  • 9.3.1. China
  • 9.3.2. Japan
  • 9.3.3. India
  • 9.3.4. Rest of Asia-Pacific
• 9.4. Rest of World

10.VALUE CHAIN ANALYSIS

11.COMPETITIVE LANDSCAPE

• 11.1. Competition Dashboard
• 11.2. Competitor Market Positioning Analysis
• 11.3. Porter Five Forces Analysis

12.COMPANY PROFILES

• 12.1. Sanofi
  • 12.1.1. Company Overview
  • 12.1.2. Key Financials
  • 12.1.3. SWOT Analysis
  • 12.1.4. Product Portfolio
  • 12.1.5. Recent Developments
• 12.2. Teva Pharmaceutical Industries Ltd.
• 12.3. X4 Pharmaceuticals, Inc.
• 12.4. BioLineRx Ltd.
• 12.5. Merck KGaA
• 12.6. GPCR Therapeutics
• 12.7. AdAlta Limited
• 12.8. Spexis Ltd.
• 12.9. GlycoMimetics
• 12.10. Abbisko Therapeutics Co. Ltd.

13.ACRONYMS & ASSUMPTION

14.ANNEXURE